- Home
- KPTI vs CCEL Comparison
KPTI vs CCEL Comparison
Compare KPTI & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- CCEL
- Stock Information
- Founded
- KPTI 2008
- CCEL 1989
- Country
- KPTI United States
- CCEL United States
- Employees
- KPTI N/A
- CCEL N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- KPTI Health Care
- CCEL Health Care
- Exchange
- KPTI Nasdaq
- CCEL Nasdaq
- Market Cap
- KPTI 51.7M
- CCEL 51.9M
- IPO Year
- KPTI 2013
- CCEL 1997
- Fundamental
- Price
- KPTI $7.36
- CCEL $4.85
- Analyst Decision
- KPTI Strong Buy
- CCEL Strong Buy
- Analyst Count
- KPTI 5
- CCEL 1
- Target Price
- KPTI $61.00
- CCEL $8.50
- AVG Volume (30 Days)
- KPTI 101.5K
- CCEL 13.6K
- Earning Date
- KPTI 05-12-2025
- CCEL 04-15-2025
- Dividend Yield
- KPTI N/A
- CCEL 4.99%
- EPS Growth
- KPTI N/A
- CCEL N/A
- EPS
- KPTI N/A
- CCEL 0.01
- Revenue
- KPTI $145,237,000.00
- CCEL $32,102,750.00
- Revenue This Year
- KPTI $4.87
- CCEL $2.49
- Revenue Next Year
- KPTI $16.29
- CCEL $0.95
- P/E Ratio
- KPTI N/A
- CCEL $304.55
- Revenue Growth
- KPTI N/A
- CCEL 2.33
- 52 Week Low
- KPTI $3.51
- CCEL $4.96
- 52 Week High
- KPTI $18.00
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- KPTI 68.69
- CCEL 29.82
- Support Level
- KPTI $5.52
- CCEL $5.38
- Resistance Level
- KPTI $6.56
- CCEL $5.76
- Average True Range (ATR)
- KPTI 0.56
- CCEL 0.39
- MACD
- KPTI 0.34
- CCEL -0.02
- Stochastic Oscillator
- KPTI 86.12
- CCEL 7.81
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.